Related Experiment Video
Updated: Jul 6, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Anti-tumor analysis of the RIG-I agonist in vitro and in vivo
Qian Wang1,2,3,4, Ziyang Song1,2,3, Bopei Cui1,2,3
1National Institutes for Food and Drug Control, Beijing, 102629, China.
Abstract:
Retinoic acid-inducible gene I (RIG-I), a key pattern recognition receptor (PRR) detecting cytosolic 5'-triphosphorylated double-stranded RNA (5'-ppp dsRNA), mediated antitumor immunity. Here, we evaluated RIG-I agonists as potential antitumor agents. To analyze the anti-tumor efficacy, we engineered a panel of 5'-PPP-modified stem-loop-structured RNAs leveraging the non-coding sequence of SARS-CoV-2. Through systematic screening, nCoV-L emerged as a potent RIG-I agonist that induced death in hepatocellular carcinomas (HCC), pulmonary carcinomas, and colorectal cancer (CRC) in vitro and suppressed tumor growth in vivo. Mechanistic studies demonstrated that nCoV-L elicited mitochondria-dependent apoptosis, supporting its potential as a broad-spectrum antitumor agent.
More Related Videos
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi
Inhibitors of Viral Protein Synthesis